We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Zymeworks announced that its partner, BeiGene has dosed the first patient in a two-arm Phase 1b/2 trial evaluating the former's HER2-targeted bispecific antibody ZW25 in combination with chemotherapy.